Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab vs Corticosteroids in COVID-19 Pneumonia
NCT04329650Phase 2Completed
- Sponsor
- Judit Pich Martínez
- Start
- Apr 2020
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of siltuximab in COVID-19 pneumonia (2 arms), sponsored by Judit Pich Martínez. Primary endpoint: Proportion of patients requiring ICU admission at 29 days. Started Apr 2020; status: completed.
02
Drugs
siltuximab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04329650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04329650.